|
SBDSP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.0128999861081E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.33650001755382E-09 |
| Normal-vs-Stage2 |
1.279960E-03 |
| Normal-vs-Stage3 |
1.6172996275543E-10 |
| Normal-vs-Stage4 |
3.17830000096109E-08 |
| Stage1-vs-Stage2 |
2.335800E-01 |
| Stage1-vs-Stage3 |
6.705600E-02 |
| Stage1-vs-Stage4 |
4.223000E-01 |
| Stage2-vs-Stage3 |
2.532400E-02 |
| Stage2-vs-Stage4 |
1.213960E-01 |
| Stage3-vs-Stage4 |
5.649800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.59220431178642E-11 |
| Normal-vs-AfricanAmerican |
8.035400E-03 |
| Normal-vs-Asian |
5.20740000009567E-07 |
| Caucasian-vs-AfricanAmerican |
5.229600E-01 |
| Caucasian-vs-Asian |
3.406400E-01 |
| AfricanAmerican-vs-Asian |
8.510200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.05559999630245E-08 |
| Normal-vs-Female |
4.40869996065629E-09 |
| Male-vs-Female |
8.653000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.8717999613408E-09 |
| Normal-vs-Age(41-60Yrs) |
5.17470000183096E-09 |
| Normal-vs-Age(61-80Yrs) |
4.27829999982698E-07 |
| Normal-vs-Age(81-100Yrs) |
1.016530E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.958200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.129000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.739200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.044200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.739000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.650400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.261700E-03 |
| Classical-VS-Follicular |
6.641500E-04 |
| Classical-VS-Other |
9.055200E-01 |
| Classical-VS-Normal |
6.01030336611075E-11 |
| Tall-VS-Follicular |
9.66450000028374E-07 |
| Tall-VS-Other |
1.538220E-01 |
| Tall-VS-Normal |
2.88440049622807E-10 |
| Follicular-VS-Other |
2.768000E-02 |
| Follicular-VS-Normal |
2.853700E-02 |
| Other-VS-Normal |
7.158900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.81299999749641E-08 |
| Normal-vs-N1 |
3.77869999956815E-07 |
| N0-vs-N1 |
4.133000E-01 |
|
|
